Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Chief Legal and Admin. Officer | February 26, 2026 | March 05, 2026 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Legal Officer | November 20, 2024 | November 22, 2024 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | SVP,General Counsel & Sec. | June 01, 2017 | June 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date February 26, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.68 · Expires 2035-12-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-02-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: One-third of the shares underlying the option become vested and exercisable on January 1, 2027, and the remaining two-thirds of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 24 months following January 1, 2027, subject to the reporting person's continued service through the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: These restricted stock units ("RSUs") vest in three substantially equal annual installments at the three anniversary dates following January 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the shares underlying the option become vested and exercisable on January 1, 2027, and the remaining two-thirds of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 24 months following January 1, 2027, subject to the reporting person's continued service through the applicable vesting date.
F2: These restricted stock units ("RSUs") vest in three substantially equal annual installments at the three anniversary dates following January 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
F3: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
Immunovant, Inc.
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 319,228 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Sale · Disposed 3,650 · Balance 319,228 F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Minerva Neurosciences, Inc.
Report date June 01, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-01 · Exercise / conversion · Acquired 17,500 · Balance 17,500 Row 2 · 2017-06-01 · Sale · Disposed 17,500 · Balance 0 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2025-04-13 | Direct | 39,774 |
Reported balance
After 2017-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-01 · Exercise / conversion · Disposed 17,500 · Balance 39,774 F2: This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016.
F2: This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 133,486 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.74 · Expires 2027-06-25 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 125,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 33,333 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2030-03-01 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 15,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2031-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 16:30 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 539 | $21.22 | $11,437.58 |
DisclosureSEC source: 0001209191-18-039211 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,872 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 539 shares by the Reporting Person on June 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 16:45 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 33,333 | $0.00 Strike: $22.31 | $0.00 |
DisclosureSEC source: 0001209191-18-006924 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires 2028-01-31 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 1, 2018, so that all of the shares subject to the option shall be vested four (4) years after January 1, 2018. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 16:45 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-006924 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Read SEC document |
| June 26, 2017 Filed Jun 26, 2017 21:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $21.74 | $0.00 |
DisclosureSEC source: 0001209191-17-041875 · doc4.xml · derivative · entry 1 Levine Mark S. · CIK 0001617236 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-06-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 26, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following June 26, 2018, so that all of the shares subject to the option shall be vested after June 26, 2021. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:33 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-17-037738 · doc4.xml · derivative · entry 3 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,774 Underlying: Common Stock · 17,500 shares Expires 2025-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested as to 25% for the shares on April 14, 2016 and then in quarterly installments over 3 years thereafter. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:33 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | SaleCommon Stock | 17,500 | $11.00 | $192,500.00 |
DisclosureSEC source: 0001209191-17-037738 · doc4.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:33 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionCommon Stock | 17,500 | $5.19 | $90,825.00 |
DisclosureSEC source: 0001209191-17-037738 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionStock Option (Right to Buy) · Derivative | 250 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002652 · doc4.xml · derivative · entry 5 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,274 Underlying: Common Stock · 250 shares Expires 2025-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests as follows: 25% on April 14, 2016; and then in quarterly installments over 3 years thereafter. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001209191-17-002652 · doc4.xml · derivative · entry 4 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,750 Underlying: Common Stock · 17,250 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests as follows: 25% on December 4, 2016 and then in quarterly installments over 3 years thereafter. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | SaleCommon Stock | 17,500 | $12.00 | $210,000.00 |
DisclosureSEC source: 0001209191-17-002652 · doc4.xml · nonDerivative · entry 3 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionCommon Stock | 250 | $5.19 | $1,297.50 |
DisclosureSEC source: 0001209191-17-002652 · doc4.xml · nonDerivative · entry 2 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | Exercise / conversionCommon Stock | 17,250 | $4.71 | $81,247.50 |
DisclosureSEC source: 0001209191-17-002652 · doc4.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:01 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001209191-16-155681 · doc4.xml · derivative · entry 2 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2026-12-13 F3 · derivative.exercise_price: The exercise price is the closing price of the Issuer's common stock on December 14, 2016. F4 · derivative.exercise_date: This option shall vest as follows: 25% on December 14, 2017 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:01 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155681 · doc4.xml · derivative · entry 1 Levine Mark S. · CIK 0001617236 · SVP,General Counsel & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on December 14, 2016. The RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on December 14, 2016. The RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.